INFIGRATINIB: 67 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
67
Total FAERS Reports
11 (16.4%)
Deaths Reported
32
Hospitalizations
67
As Primary/Secondary Suspect
1
Life-Threatening
May 28, 2021
FDA Approved
Discontinued
Status
FDA Application: 214622 ·
Patent Expires: Dec 11, 2034 · First Report: 20160610 · Latest Report: 20221118
What Are the Most Common INFIGRATINIB Side Effects?
#1 Most Reported
Fatigue
16 reports (23.9%)
#2 Most Reported
Stomatitis
12 reports (17.9%)
#3 Most Reported
Off label use
11 reports (16.4%)
All INFIGRATINIB Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Fatigue | 16 | 23.9% | 3 | 7 |
| Stomatitis | 12 | 17.9% | 0 | 4 |
| Off label use | 11 | 16.4% | 3 | 2 |
| Alopecia | 10 | 14.9% | 2 | 4 |
| Decreased appetite | 10 | 14.9% | 4 | 4 |
| Diarrhoea | 10 | 14.9% | 0 | 7 |
| Nausea | 9 | 13.4% | 2 | 4 |
| Blood phosphorus increased | 8 | 11.9% | 3 | 2 |
| Skin exfoliation | 8 | 11.9% | 1 | 3 |
| Vomiting | 8 | 11.9% | 0 | 4 |
| Death | 7 | 10.5% | 7 | 1 |
| Malignant neoplasm progression | 7 | 10.5% | 1 | 1 |
| Onychomadesis | 7 | 10.5% | 0 | 2 |
| Vision blurred | 7 | 10.5% | 0 | 2 |
| Constipation | 6 | 9.0% | 0 | 4 |
| Dehydration | 6 | 9.0% | 1 | 5 |
| Dry eye | 6 | 9.0% | 1 | 1 |
| Dry mouth | 6 | 9.0% | 1 | 3 |
| Pain in extremity | 6 | 9.0% | 1 | 3 |
| Arthralgia | 5 | 7.5% | 0 | 2 |
Who Reports INFIGRATINIB Side Effects? Age & Gender Data
Gender: 58.3% female, 41.7% male. Average age: 54.2 years. Most reports from: US. View detailed demographics →
Is INFIGRATINIB Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2016 | 1 | 0 | 1 |
| 2018 | 2 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 5 | 0 | 4 |
| 2021 | 13 | 2 | 7 |
| 2022 | 28 | 7 | 15 |
What Is INFIGRATINIB Used For?
| Indication | Reports |
|---|---|
| Cholangiocarcinoma | 42 |
Official FDA Label for INFIGRATINIB
Official prescribing information from the FDA-approved drug label.